ImmunityBio Target of Unusually Large Options Trading (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX) saw unusually large options trading activity on Friday. Investors acquired 9,749 call options on the company. This is an increase of 125% compared to the average volume of 4,330 call options.

Analyst Ratings Changes

IBRX has been the subject of a number of research analyst reports. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday. Piper Sandler decreased their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th.

Hedge Funds Weigh In On ImmunityBio

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of ImmunityBio by 1.6% in the first quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company’s stock valued at $72,708,000 after purchasing an additional 211,065 shares during the last quarter. Sheets Smith Wealth Management lifted its position in ImmunityBio by 380.8% during the 1st quarter. Sheets Smith Wealth Management now owns 945,720 shares of the company’s stock worth $5,079,000 after buying an additional 749,041 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of ImmunityBio by 37.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock worth $3,928,000 after buying an additional 170,742 shares during the last quarter. Clearwater Capital Advisors LLC grew its holdings in shares of ImmunityBio by 8.9% in the 2nd quarter. Clearwater Capital Advisors LLC now owns 482,549 shares of the company’s stock valued at $3,050,000 after acquiring an additional 39,250 shares in the last quarter. Finally, Blair William & Co. IL increased its position in shares of ImmunityBio by 106.3% in the first quarter. Blair William & Co. IL now owns 313,542 shares of the company’s stock valued at $1,684,000 after acquiring an additional 161,530 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Stock Up 26.4 %

Shares of NASDAQ:IBRX opened at $5.32 on Friday. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of -5.48 and a beta of 1.02. ImmunityBio has a 12 month low of $1.62 and a 12 month high of $10.53. The company’s fifty day simple moving average is $3.72 and its 200 day simple moving average is $5.35.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.53 million. Research analysts expect that ImmunityBio will post -0.86 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.